MMP
Matrix metalloproteinases (MMPs) are a family of zinc-dependent neutral endopeptidases, generally consisting of a single peptide, a propeptide domain, a catalytic domain with a highly conserved zinc-binding site and a haemopexin-like domain, that catalyze the degradation of all components of the extracellular matrix. Multiple studies have shown that MMPs are overexpressed in malignant tumor and involved in the process of tumor growth, invasion and metastasis. Thus, synthetic and naturally occurring MMP inhibitions have been investigated as anti-cancer agents for the treatment of a variety of cancers, which are divided into three pharmacologic categories, including collagen peptidomimetics and nonpeptidomimetics, tetracycline derivatives and bisphosphonates.
- C4331 MMP-13 InhibitorSummary: MMP-13 inhibitor
- C4501 cis-ACCPSummary: type IV collagen-specific MMP-2 and MMP-9 inhibitor
- C5598 MMP-2/MMP-9 Inhibitor ISummary: potent inhibitor of matrix metalloproteinase-2 (MMP-2) and MMP-9
- C5615 MMP-2 Inhibitor ISummary: reversible inhibitor of matrix metalloproteinase (MMP)-2
- B4686 TAPI-12 CitationTarget: MMPSummary: TACE/ADAM17 inhibitor
- A4432 ARP 1001 CitationTarget: MMPSummary: Selective MMP-2 inhibitor
- A4433 ARP 1011 CitationSummary: MMP inhibitor,potent and selective
- A4434 CL 82198 hydrochlorideSummary: Selective MMP-13 inhibitor
- A4435 CP 471474Summary: Broad spectrum MMP inhibitor
- A4437 ONO 4817Summary: MMP inhibitor